Activation of FOXO3a, by paclitaxel, antibodies against EGFR (cetuximab)/HER2 (trastuzumab), or mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) 1/2 inhibitor, results in apoptosis in breast cancer cells, indicating that activation of FOXO3a inhibits proliferation and development of breast cancer [35]–[37]. Here, EGFR is linked to breast cancer.